Research programme: breast cancer resistance protein bispecific antibodies - Kenjockety Biotechnology
Alternative Names: ABCG2 TAA BsAbs; BCRP TAA BsAbsLatest Information Update: 09 Dec 2021
Price :
$50 *
At a glance
- Originator Kenjockety Biotechnology
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Membrane protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 01 Dec 2021 Breast cancer resistance protein bispecific antibodies are available for licensing as of 01 Dec 2021 (https://kenjocketybio.com/development#pipeline)
- 25 Nov 2021 Kenjockety Biotechnology has patents pending for efflux pump-cancer antigen multi-specific antibodies and compositions and methods related thereto in Canada
- 25 Nov 2021 Early research in Haematological malignancies in USA (unspecified route) prior to November 2021 (Kenjockety Biotechnology pipeline, November 2021)